Philip R Krause

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi Goals of stability evaluation throughout the vaccine life cycle
    Philip R Krause
    FDA CBER OVRR DVP, Bethesda, MD 20892 4555, USA
    Biologicals 37:369-78; discussion 421-3. 2009
  2. ncbi Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia
    Masahiro Ohashi
    FDA CBER, HFM 457, 29 Lincoln Drive, Bethesda, MD 20892 4555, USA
    J Virol 85:3030-2. 2011
  3. ncbi Herpes simplex virus 2 microRNA miR-H6 is a novel latency-associated transcript-associated microRNA, but reduction of its expression does not influence the establishment of viral latency or the recurrence phenotype
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 85:4501-9. 2011
  4. ncbi Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
    Daniel A Salmon
    National Vaccine Program Office, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Ave, Washington, DC 20201, USA
    Pediatrics 127:S78-86. 2011

Collaborators

Detail Information

Publications4

  1. ncbi Goals of stability evaluation throughout the vaccine life cycle
    Philip R Krause
    FDA CBER OVRR DVP, Bethesda, MD 20892 4555, USA
    Biologicals 37:369-78; discussion 421-3. 2009
    ..At each phase in the product life cycle, it is important to consider the goals of stability evaluation and to perform appropriate statistical analyses in order to assure and reach appropriate conclusions about product quality...
  2. ncbi Spread of herpes simplex virus to the spinal cord is independent of spread to dorsal root ganglia
    Masahiro Ohashi
    FDA CBER, HFM 457, 29 Lincoln Drive, Bethesda, MD 20892 4555, USA
    J Virol 85:3030-2. 2011
    ....
  3. ncbi Herpes simplex virus 2 microRNA miR-H6 is a novel latency-associated transcript-associated microRNA, but reduction of its expression does not influence the establishment of viral latency or the recurrence phenotype
    Shuang Tang
    Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    J Virol 85:4501-9. 2011
    ..We hypothesize that viral miRNAs associated with LAT expression are likely to work collectively, contributing to the phenotype attributed to the LAT...
  4. ncbi Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program
    Daniel A Salmon
    National Vaccine Program Office, Office of Public Health and Science, Department of Health and Human Services, 200 Independence Ave, Washington, DC 20201, USA
    Pediatrics 127:S78-86. 2011
    ..These efforts improved monitoring of 2009 H1N1 vaccine safety, hold promise for enhancing future national monitoring of vaccine safety, and may ultimately help improve public confidence in vaccines...